Comment Infliximab biosimilar CTP13 in Crohn's disease
The first biosimilar monoclonal antibody to receive marketing authorisation from the European Medicines Agency was the infliximab biosimilar CTP13 in 2013.1 At the time of registration equivalence...
View ArticleArticles Efficacy and safety of biosimilar CTP13 compared with originator...
This study showed noninferiority of CTP13 to infliximab in patients with active Crohn's disease. Biosimilar CTP13 could be a new option for the treatment of active Crohn's disease.
View ArticleEuropean Medicines Agency Accepts Takedas Marketing Authorization Application...
Additional treatment modality would provide greater choice in how patients receive gutselective biologic vedolizumab Vedolizumab set to be the only maintenance therapy to offer the option of...
View ArticleThis Mouse Model is Getting Us Closer to Treating Inflammatory Bowel Disease
An estimated 10 million people suffer from inflammatory bowel disease IBD worldwide. IBD is the umbrella term for the two conditions Crohn disease and ulcerative colitis. They are chronic immunological...
View ArticleuBiome Awarded Eighth Patent for the Characterization of Skin Related Conditions
The leader in microbial genomics was granted a patent for characterizing skin conditions such as eczema dry skin photosensitivity and acne.SAN FRANCISCO PRWEB April 01 2019 uBiome announces the issue...
View ArticleHuman medicines European public assessment report EPAR Entyvio vedolizumab...
Human medicines European public assessment report EPAR Entyvio vedolizumab Colitis UlcerativeCrohn Disease Date of authorisation 22052014 Revision 12 Status Authorised
View ArticlePredictImmunes first prognostic test for IBD PredictSURE IBD launches in the...
The worlds first validated prognostic test for inflammatory bowel disease IBD is now available via Cambridge University Hospitals NHS Foundation Trusts Genomic Laboratory Hub PredictImmune developers...
View ArticleCDISC to Develop Data Standards for Crohns Disease With Support from the...
CDISC will develop the first global nonproprietary clinical data standards for Crohns disease with a grant award of $1 million from The Leona M. and Harry B. Helmsley Charitable Trust. CDISC Standards...
View ArticlePatentpending probiotic could disrupt Crohn's disease biofilms
Case Western Reserve University Probiotics typically aim to rebalance bacteria populations in the gut but new research suggests they may also help break apart stubborn biofilms. Biofilms are living...
View ArticleWhite Blood Cell WBC in Stool
Related MedlinePlus Pages Bacterial Infections Crohn's Disease Diarrhea Ulcerative Colitis
View ArticleBiosimilar to Infliximab Is Effective for Inducing Remission in Crohn Disease
The first randomized headtohead study demonstrates noninferiority of CTP13.
View ArticleQuick Take Efficacy and safety of biosimilar CTP13 compared with originator...
Antitumor necrosis factor TNF therapies are commonly used in the treatment of patients with moderate to severe Crohns disease. However due to the high costs of antiTNF medications biosimilar...
View ArticleSimplified MRI Scoring Good for Gauging Crohns
MedPage Today As good as colonoscopy for assessing mucosal healing
View ArticlePAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS...
PAION AG Key words Research UpdatePAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE COSMO PHARMACEUTICALS IN THE U.S.08Apr2019 1248 CETCESTDisclosure of an inside...
View ArticleOlder Patients With Crohn Disease May Benefit From Early Combo Tx
MONDAY April 8 2019 A post hoc analysis of data from a randomized trial shows no difference between older and younger patients for the safety and efficacy of early combined immunosuppression therapy...
View ArticleDiscovering Infectious Determinants of Chronic Diseases Hospitals Academia &...
Initiatives underway to advance regenerative medicine program identify cause of chronic illnesses such as Lyme disease Bartonellosis rheumatoid arthritis lupus neuropsychiatric diseases and Crohns...
View ArticleGastroenterologist Dr. David Yamini Named a Top Doctor in Los Angeles Magazine
Dr. David Yamini a double boardcertified gastroenterologist was recently featured as a 2019 Top Doctor by Los Angeles Magazine. Dr. Yamini serves patients from offices in Santa Monica and Beverly Hills...
View ArticleHuman medicines European public assessment report EPAR Inflectra infliximab...
Human medicines European public assessment report EPAR Inflectra infliximab Arthritis PsoriaticSpondylitis AnkylosingColitis UlcerativePsoriasisCrohn DiseaseArthritis Rheumatoid Date of authorisation...
View ArticleInfliximab Biosimilar CTP13 Noninferior in Active Crohn's Disease
The infliximab biosimilar CTP13 is noninferior to infliximab for treating patients with active Crohn's disease according to a randomized controlled trial. Reuters Health Information
View ArticleEdible antibodies to treat gastrointestinal disorders
Belgian scientists have developed a new antibody technology that combines the advantages of antibodybased therapies with the convenience of oral drug administration. These antibodies are manufactured...
View Article